Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine

What Was Tested

Researchers studied CGRP (Calcitonin Gene-Related Peptide) in the context of migraine in this randomized controlled trial publication.

Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) signaling are being explored as prophylactic treatments for migraine.

Erenumab (AMG 334) is the first potent, selective, and competitive human mAb antagonist of the CGRP receptor.

Who Took Part

PubMed indexes the participants as teenagers, young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized and double-blind study.

The participants were allocated by chance, so the CGRP (Calcitonin Gene-Related Peptide) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on CGRP (Calcitonin Gene-Related Peptide), so expectations could not easily colour the readings.

What Was Measured

The subject headings attached to it are Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide, Calcitonin Gene-Related Peptide Receptor Antagonists, Healthy Volunteers, Migraine Disorders and Signal Transduction.

What This Means in Plain Language

The paper is a randomized and double-blind study of CGRP (Calcitonin Gene-Related Peptide) in people with migraine.

The publication is from 2018 (Clinical pharmacology and therapeutics), a journal based in United States.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.